Keyword: Soliris

The deal will see Alexion work with Complement to take a C6 complement inhibitor through phase 1b and decide whether to execute a takeover.

The success positions Alexion to file for approval and shield itself from an anticipated assault on its paroxysmal nocturnal hemoglobinuria franchise.

Alexion hit key endpoints for its experimental phase 3 drug ALXN1210 in patients with a life-threatening ultrarare blood disorder.

Alexion is slashing its workforce by around 20% and closing sites in a bid to save $250 million a year, with R&D bearing the brunt.

Apellis reported positive midstage data for its lead candidate in age-related macular degeneration shortly after a $60 million series E raise.

Omeros has defended the data supporting its mooted rival to Soliris after STAT sought answers to questions raised by a short seller.

The CEO of Akari Therapeutics has quit amid a probe into the release of phase 2 data and a related analyst report.

Akari Therapeutics has put its CEO on administrative leave pending investigation of an inaccurate analyst report.

Impax, Alexion and Depomed all have their own problems to worry about, and they're all counting on the new CEOs they just tapped to turn the situation around.